Aligos Therapeutics, Inc.
For the period ended Mar 31, 2025. Filed May 6, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2025 · Filed May 6, 2025
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Unregistered Sales of Equity Securities and Use of Proceeds
Item 2. Unregistered Sales of Equity Securities and Use of Proceeds.
Unregistered sales of equity securities
In January 2024, two investors net exercised their 2023 Pre-Funded Warrants to purchase an aggregate of 146,484 shares of Common stock and were issued 146,468 shares of Common Stock.
Use of proceeds
None.
Issuer purchasers of equity securities
None.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.